Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04501081 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Natural History of Autosomal Dominant Hearing Loss

StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

The 50 most recent of 235 record versions are accounted for below. See every version on ClinicalTrials.gov ↗

  1. Minor 9 versions Re-verified since Oct 1, 2024, no change to tracked fieldsv227-v235
  2. Minor Eligibility criteria expanded, about 7 wordsv226 See this version in full on ClinicalTrials.gov ↗
  3. Minor 3 versions Re-verified since May 22, 2024, no change to tracked fieldsv223-v225
  4. Minor Study description revisedv222 See this version in full on ClinicalTrials.gov ↗
  5. Minor 10 versions Re-verified since Aug 12, 2022, no change to tracked fieldsv212-v221
Show 26 earlier versionsHide 26 earlier versions
  1. Minor Eligibility criteria expanded, about 14 words Study description expanded, about 203 wordsv211 Show 1 more changeShow less
    • Study description expanded, about 203 words

    See this version in full on ClinicalTrials.gov ↗

  2. Minor 25 versions Re-verified since May 26, 2022, no change to tracked fieldsv186-v210
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Background: Hereditary hearing loss is one of the most common sensory disabilities affecting newborns. The main options for people with hereditary hearing loss are hearing aids and cochlear implants. Both options have their limitations and do not restore biological hearing. Researchers want to learn if gene editing might be a treatment option. Objective: To understand the genes that cause non-syndromic autosomal dominant hearing loss (DFNA) in people with DFNA as well as their family members. Eligibility: People age 3 99 who have DFNA, affected family members of enrolled participants with DFNA, and unaffected family members of enrolled participants Design: Participants will be screened with a medical and hearing history. Their medical records will be reviewed. Participants will have hearing tests. They will wear headphones or earplugs. They will listen to tones, sounds, and words and may be asked to describe what they hear. Participants will have balance tests. For these, they will wear googles as they watch moving lights or as cold or warm air is blown into their ears. They will sit in a spinning chair in a quiet, dark booth. From a reclined position, they will raise their head while listening to clicking sounds. Participants will have blood drawn through a needle in the arm. Some blood will be used for gene testing. Some participants will have 2 skin biopsies. The skin will be washed, and a numbing medicine will be injected. Two small pieces of skin will be removed. Participants may have a physical exam. Participation will last for up to 20 years. Participants may give medical updates once a year.
Trial Details
NCT Number NCT04501081
Lead Sponsor National Institute on Deafness and Other Communication Disorders (NIDCD)
Conditions Hearing Loss
Enrollment 1,100 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov